EUVIMEDEUVIMED entdecken
Open Access

Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

Jessica R Tait, Marina Harper iD, Sara Cortés-Lara, Kate E Rogers, Carla López-Causapé, Thomas R Smallman, Yinzhi Lang, Wee Leng Lee, Jieqiang Zhou, Jürgen B Bulitta iD, Roger L Nation, John D Boyce iD und 2 weitere

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00414-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Jessica R Tait und 13 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: DHAC | National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug-resistant hypermutable P. aeruginosa isolates in the hollow-fiber infection model (HFIM). Isolates CW41, CW35, and CW44 (ceftolozane-tazobactam MICs of 4, 4, and 2 mg/L, respectively) from adults with CF were exposed to simulated representative epithelial lining fluid pharmacokinetics of ceftolozane-tazobactam in the HFIM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPseudomonas InfectionsAdultHumansPseudomonas aeruginosaCephalosporinsTazobactamAnti-Bacterial AgentsMitomycinMicrobial Sensitivity TestsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

dynamic in vitro modelmechanism-based modelingpharmacodynamicswhole-genome sequencing

Substanzen

ceftolozaneCephalosporinsceftolozane, tazobactam drug combinationTazobactamAnti-Bacterial AgentsMitomycin

Autor:innen und Institutionen

  • Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Victoria, Australia.
  • Servicio de Microbiología, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain.
  • CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.

ORCID-Profile: Marina Harper, Jürgen B Bulitta, John D Boyce, Antonio Oliver, Cornelia B Landersdorfer

Förderung

  • DHAC | National Health and Medical Research Council

Zitieren

APA

Tait, J. R., Harper, M., Cortés-Lara, S., Rogers, K. E., López-Causapé, C., Smallman, T. R., Lang, Y., Lee, W. L., Zhou, J., Bulitta, J. B., Nation, R. L., Boyce, J. D., Oliver, A., & Landersdorfer, C. B. (2023). Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00414-23

Vancouver

Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, et al. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00414-23

BibTeX
@article{Tait2023,
  author = {Tait, Jessica R and Harper, Marina and Cortés-Lara, Sara and Rogers, Kate E and López-Causapé, Carla and Smallman, Thomas R and Lang, Yinzhi and Lee, Wee Leng and Zhou, Jieqiang and Bulitta, Jürgen B and Nation, Roger L and Boyce, John D and Oliver, Antonio and Landersdorfer, Cornelia B},
  title = {Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00414-23}
}
Kostenlos starten →